HRMYHarmony Biosciences Holdings, Inc.

$40.31+24% 1Y

$40.31

$25.9052 weeks$42.88

HRMY in its own filings

Nothing in HRMY's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

120

Events found in the filings · across 455 filings · the record starts in 2020

Hard flags: none
Hard flags
Most recent filing: Aug 4, 2026
Most recent filing · Form 10-Q
Record starts: Mar 12, 2020
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 3, 2026
SEC comment-letter activity11 occurrences: 2025-04-15

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 4, 2026Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile.Earnings release · press release
Jul 16, 2026Departure of Chief Financial Officer On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.Earnings release · Form 8-K
May 7, 2026WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion.Earnings release · press release
Apr 14, 2026Departure of Chief Financial Officer On April 14, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) announced that Sandip Kapadia, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of April 14, 2026 to pursue other career opportunities.Director or officer change · Form 8-K
Apr 2, 2026Appointment of Chief Operating Officer; Resignation of Director On April 2, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) named Peter Anastasiou the Company’s Senior Executive Vice President and Chief Operating Officer (“COO”), effective April 2, 2026.Director or officer change · Form 8-K
Feb 24, 2026WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy.Earnings release · press release
Jan 12, 2026WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy.Earnings release · press release
Nov 4, 2025WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth)Earnings release · press release
Oct 23, 2025PLYMOUTH MEETING, Pa., October 23, 2025 /Business Wire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following:.Earnings release · press release
Sep 24, 2025About the RECONNECT Study.Regulation FD disclosure · press release